Continuing improvement in early diagnosis and treatment for cancer patients has led to an increase in cancer survival rates over the last decade. A recent population-based study described how cancer survival rates have increased across all cancer types, mainly in high-income countries [1]. As the number of cancer survivors increases, the health-related quality of life (HRQOL) for those patients is one of the biggest concerns. Many chemotherapeutic agents can cause chemotherapy-induced peripheral neuropathy (CIPN), characterized by tingling, numbness, and burning pain in both hands and feet. Those neuropathy-related symptoms have a negative impact on HRQOL in cancer patients and survivors [2]. Moreover, CIPN can lead to dose reduction or early cessation of chemotherapy because of the dose-dependent relationship of chemotherapeutic drugs on CIPN prevalence.

The incidence of CIPN is high, up to 68% within the first month, 60% at three months, and 30% at six months after chemotherapy [3]. The major chemotherapeutics that cause neuropathy include taxanes, platinum compounds, vinca alkaloids, proteasome inhibitors, and immunomodulating drugs. Although each drug has a different mechanism for causing neuropathy, the primary mechanism shared by these agents are morphologic and biochemical alterations in the dorsal root ganglion (DRG) and spinal cord [4]. Previous studies have demonstrated that the respective mechanism is as follows: disruption of axonal transport, ion channel dysregulation, mitochondrial and oxidative stress, neuroinflammation, and immunological processes [4,5].

Numerous pre-clinical studies have shown efficacy in the treatment of established CIPN or the prevention of CIPN. Modulation of ion channels, including the sodium [6,7], potassium [8,9], and calcium channel [10], have shown promising efficacy in pre-clinical studies. However, the clinical efficacy of these targeting drugs is still limited [11]. Duloxetine, a serotonin-norepinephrine reuptake inhibitor, is the only chemotherapeutic drug which has proven effective in a randomized clinical trial [12]. Topical menthol or capsaicin has been shown to improve neuropathy-related symptoms in a small non-randomized clinical study [13,14]. Therefore, there is still no well-defined treatment protocol.

Recent pre-clinical research has found novel preventive
and therapeutic targets, including a specific organic anion transporting polypeptide [15], Sphingosine-1-phosphate receptor 1 [16], and an angiotensin II type 1 receptor [17]. These promising targets have the potential to be translated into clinical practice for the treatment of CIPN.

In this issue, Yin et al. [18] found that neurotensin receptor 1 (NTSR1), which is widely distributed in the spinal cord and DRG, plays significant roles in spinal- and supraspinal-level pain processing in a rat model of CIPN. NTSR1 agonist may also have an indirect effect on the serotonergic pathway. Therefore, NTSR1 could provide new therapeutic targets for a promising treatment for cancer survivors with CIPN.

There are several barriers to turning these laboratory discoveries into applications in clinical practice. The main problems include the lack of communication between basic scientists and clinicians, a lack of trained interdisciplinary researchers, a lack of access to shared resources, and complex ethical issues [19]. However, investigators working on translational research must continue their efforts to break these barriers down. It can lead them to a pathway for potential therapeutics. Therefore, under the guidance of the pre-clinical literature, we should continue to identify novel targets that may help improve CIPN and prove their clinical efficacy through the proper application.

**CONFLICT OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**FUNDING**

No funding to declare.

**ORCID**

Eunsoo Kim, https://orcid.org/0000-0001-9978-4973

**REFERENCES**

1. Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TÅ, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 2019; 20: 1493-505.
2. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013; 31: 2699-707.
3. Seretty M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014; 155: 2461-70.
4. Sisignano M, Baron R, Scholich K, Geisslinger G. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. Nat Rev Neurol 2014; 10: 694-707.
5. Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2019; 25: 6295-301.
6. Li Y, North RY, Rhines LD, Tatsui CE, Rao G, Edwards DD, et al. DRG voltage-gated sodium channel 1.7 is upregulated in paclitaxel-induced neuropathy in rats and in humans with neuropathic pain. J Neurosci 2018; 38: 1124-36.
7. Bankar G, Goodchild SJ, Howard S, Nelkenbrecher K, Waldbrook M, Dourado M, et al. Selective NaV1.7 antagonists with long residence time show improved efficacy against inflammatory and neuropathic pain. Cell Rep 2018; 24: 3133-45.
8. Poupon L, Lamoine S, Pereira V, Barrière D, Loilignier S, Giraudet F, et al. Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology 2018; 140: 43-61.
9. Kim K, Jeong W, Jun IG, Park JY. Antiallodynic and anti-inflammatory effects of intrathecal R-PIA in a rat model of vincristine-induced peripheral neuropathy. Korean J Anesthesiol 2020. doi: 10.4097/kja.19481.
10. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 2004; 109: 150-61.
11. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32: 1941-67.
12. Smith EM, Pang H, Cirrincione C, Fleshman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013; 309: 1359-67.
13. Fallon MT, Storey DJ, Krishan A, Weir CJ, Mitchell R, Fleetwood-Walker SM, et al. Cancer treatment-related neuropathic pain: proof of concept study with menthol--a TRPM8 agonist. Support Care Cancer 2015; 23: 2769-77.
14. Anand P, Elsafa E, Privitera R, Naikoo K, Yiangou Y, Donati P, et al. Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. J Pain Res 2019; 12: 2039-
15. Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, et al. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest 2018; 128: 816-25.

16. Stockstill K, Doyle TM, Yan X, Chen Z, Janes K, Little JW, et al. Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. J Exp Med 2018; 215: 1301-13.

17. Kim E, Hwang SH, Kim HK, Abdi S, Kim HK. Losartan, an angiotensin II type 1 receptor antagonist, alleviates mechanical hyperalgesia in a rat model of chemotherapy-induced neuropathic pain by inhibiting inflammatory cytokines in the dorsal root ganglia. Mol Neurobiol 2019; 56: 7408-19.

18. Yin M, Kim YO, Choi JI, Jeong S, Yang SH, Bae HB, et al. Antinociceptive role of neurtensin receptor 1 in rats with chemotherapy-induced peripheral neuropathy. Korean J Pain 2020; 33: 318-25.

19. Hait WN. Translating research into clinical practice: deliberations from the American Association for Cancer Research. Clin Cancer Res 2005; 11: 4275-7.